Dibenzothiepin | 220-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: Dibenzothiepin
• 英文别名: dibenzothiepine；benzo[d][1]benzothiepine
• CAS: 220-07-5
• 化学式: C₁₄H₁₀S
• 分子量: 210.299
• InChiKey: FKKFMCSXGHRBON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Drugs for incontinence
  申请人：——

  公开号：US20030203899A1

  公开（公告）日：2003-10-30

  Use in the incontinence of one or more of the following classes of drugs selected from the following: B) salified and non salified nitric oxide-donor drugs, of formula: A-X 1 —N(O) z , B′) nitrate salts of drugs used for the incontinence, and which do not contain in the molecule a nitric oxide donor group; C) organic or inorganic salts of compounds inhibiting phosphodiesterases.

  在选择的以下药物类别中使用一种或多种药物来治疗尿失禁：B) 含盐和不含盐的一氧化氮供体药物，化学式为：A-X1—N(O)z，B′) 用于治疗尿失禁的硝酸盐药物，且分子中不含一氧化氮供体基团；C) 抑制磷酸二酯酶的有机或无机盐化合物。
• [EN] NOVEL TETRACYCLIC TETRAHYDROFURAN DERIVATIVES<br/>[FR] NOUVEAUX DERIVES TETRACYCLIQUES DE TETRAHYDROFURANE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005121113A1

  公开（公告）日：2005-12-22

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives of Formula (I), an N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof wherin the variables are declared as in Claim 1. These compound have binding affinities towards serotonin receptors, in particular 5­HT2A and 5-HT2c receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine (NE) reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production.

  这项发明涉及公式（I）的新型取代四环四氢呋喃衍生物，其为N-氧化物形式，药学上可接受的加盐物或其立体化学异构体形式，其中变量如权利要求书1中所述。这些化合物具有对5-羟色胺受体，特别是5-HT2A和5-HT2c受体，多巴胺受体，特别是多巴胺D2受体以及去甲肾上腺素（NE）再摄取抑制性能的结合亲和力，包括根据本发明的化合物的药物组合物，其用作药物，特别是用于预防和/或治疗一系列精神疾病和神经系统疾病，特别是某些精神病性、心血管和胃动力紊乱，以及其生产方法。
• Anti-proliferative drugs
  申请人：——

  公开号：US20040029860A1

  公开（公告）日：2004-02-12

  The present invention relates to methods for the treatment of diseases associated with hyper-proliferation of cells by administering to a subject in need a therapeutically effective amount of at least one psychotropic agent. Specific proliferative diseases against which psychotropic agents were found to be effective are cancer, including multi-drug resistant cancer and diseases associated with hyper-proliferation of the skin cells, such as psoriasis and hyperkeratosis.

  本发明涉及通过向需要的受试者施用至少一种精神药物的治疗有效剂量来治疗与细胞过度增殖相关的疾病的方法。发现精神药物对其有效的特定增殖性疾病包括癌症，包括多药耐药性癌症和与皮肤细胞过度增殖相关的疾病，如银屑病和角化过度。
• Insecticidal tricyclic derivatives
  申请人：Argentine A. Joseph

  公开号：US20060111342A1

  公开（公告）日：2006-05-25

  It has now been found that certain tricyclic derivatives have provided unexpected insecticidal activity. These compounds are represented by formula I: wherein R 1 through R 8 , inclusively, and X and Y are fully described. Compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to the locus where insects are present or are expected to be present.

  现已发现某些三环衍生物具有出乎意料的杀虫活性。这些化合物由公式I表示：其中R1至R8，包括X和Y都有详细说明。还公开了包含公式I中至少一种化合物的杀虫有效量的组合物，以及可选地，至少一种第二化合物的有效量，与至少一种杀虫兼容载体；以及控制昆虫的方法，包括将所述组合物应用于昆虫存在或预计存在的地点。
• Tricyclic fused heterocycle compounds, process for preparing the same and use thereof
  申请人：Nippon Suisan Kaisha, Ltd., a Japan corporation

  公开号：US20030220360A1

  公开（公告）日：2003-11-27

  Compounds represented by formula (1), 1 wherein X is, for example, CH, CH 2 , CHR (wherein R is a lower alkyl group or a substituted lower alkyl group) or CRR′ (wherein R and R′ are the same as the above defined R); Y is, for example, CH, CH 2 or C═O; Z is, for example, O, S, S═O or SO 2 ; U is C or N; R 1 to R 4 are each independently, for example, a hydrogen atom, OR, SR (wherein R is the same as defined above), or an aromatic ring, a substituted aromatic ring or a heterocycle; at least one of R 5 and R 8 is, for example, OH and the remaining of R 5 and R 8 are each independently, for example, a hydrogen atom or OH, optical isomers thereof, conjugates thereof or pharmaceutically acceptable salts thereof are provided. These compounds are characterized in having a wide range of pharmacological actions such as an excellent relaxing action of tracheal smooth muscles, an inhibition of airway hypersensitivity and an inhibition of infiltration of inflammatory cells into the airway and, in addition, high safety.

  化学式（1）所代表的化合物，其中X可以是例如CH、CH2、CHR（其中R是较低的烷基或取代的较低烷基）或CRR'（其中R和R'与上述定义的R相同）；Y可以是例如CH、 或C═O；Z可以是例如O、S、S═O或SO2；U可以是C或N；R1到R4可以各自独立地是例如氢原子、OR、SR（其中R与上述定义的相同）或芳香环、取代芳香环或杂环；其中至少一个R5和R8可以是例如OH，而R5和R8的其余部分可以各自独立地是例如氢原子或OH，其光学异构体、共轭体或药学上可接受的盐也提供了。这些化合物具有广泛的药理作用，例如优异的松弛气管平滑肌作用、抑制气道过敏和抑制炎症细胞浸润到气道，并且具有高度的安全性。